Agemica

Therapy Design AI

Predict safe repurposed drug combinations from disease omics.

Vaccine Design AI

Design peptide and mRNA vaccines for cancer and aging targets.

Validation

Track ex-vivo cancer response and healthy-cell selectivity.

Our approach

A new standard in AI discovery.

From disease signals to promising therapies. Guided by AI. Tested in human ex-vivo models.

01

Rank

Find promising combinations.

02

Test

Test in human ex-vivo models.

Cancer modelHealthy cells

03

Kill

Measure cancer response and healthy-cell safety.

04

Advance

Move the strongest candidates toward further studies.

For illustrative purposes.

News & Insights

All Articles

5/01/2026

Cancer cell death across models, observed activity in controlled ex vivo systems.

Selectivity on healthy tissue, the difference between drug and poison.

Rank the combination, test what matters. Decompose, search, rank.

Leadership

Founder

Prof. Ronjon Nag

AI founder and Stanford genetics adjunct professor.

Cambridge PhDMIT MS

Co-Founder

Dr. Yasaman Kalantar-Motamedi

Computational biologist focused on AI drug discovery and multi-omics.

Cambridge PhDUCL research

Scientific Advisor

Prof. Michael Snyder

Stanford genomics leader in multi-omics and precision medicine.

Stanford GeneticsMulti-omics

Scientific Advisor

Prof. Jayakumar Rajadas

Drug delivery and regenerative biomaterials expert.

Stanford ADDReB LabDrug delivery

Advisor

Anastasiya Giarletta

Principal, R42 Group — AI, longevity, and founder ecosystem.

R42 GroupPortfolio

Media

Talk / AI

Prof. Ronjon Nag talks AI

Podcast / Longevity

How AI is redesigning longevity

Lecture / Machine learning

AI / Machine Learning Bootcamp

Media library

Agemica's mission is to increase the Healthy Human Life Span to 150 Years